HYPERTENSION, PULMONARY
Clinical trials for HYPERTENSION, PULMONARY explained in plain language.
Never miss a new study
Get alerted when new HYPERTENSION, PULMONARY trials appear
Sign up with your email to follow new studies for HYPERTENSION, PULMONARY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Major drug trial extends to track long-term effects in 1,000 PAH patients
Disease control ENROLLING_BY_INVITATIONThis study continues testing ralinepag, an experimental medication for pulmonary arterial hypertension (PAH), to understand its long-term safety and effectiveness. It enrolls 1,000 participants who have already taken ralinepag in previous studies and are already on standard PAH m…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: United Therapeutics • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for kids with rare, deadly lung disease
Disease control OngoingThis study is testing whether adding a drug called selexipag to standard treatments can slow down the worsening of pulmonary arterial hypertension (PAH) in children aged 2 to 18. PAH is a rare, serious disease that causes high blood pressure in the lungs. The trial will compare s…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: Actelion • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New hope for kids with rare, deadly lung disease
Disease control OngoingThis study tested the safety and correct dosing of a drug called riociguat in children aged 6 to 18 with pulmonary arterial hypertension (PAH), a serious condition causing high blood pressure in the lungs. Researchers carefully adjusted the dose for each child based on their age,…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated Mar 20, 2026 14:48 UTC
-
New drug tested to ease strain on the heart and lungs
Disease control OngoingThis study is testing an investigational drug called sotatercept to see if it can help adults with a specific type of high blood pressure in the lungs caused by heart failure. The main goals are to see if the drug reduces resistance in the lung's blood vessels and improves how fa…
Matched conditions: HYPERTENSION, PULMONARY
Phase: PHASE2 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Mar 18, 2026 14:40 UTC